Resource impact statement

No significant resource impact is anticipated

We do not expect this guidance to have a significant impact on resources; that is, it will be less than £5 million per year in England (or £9,100 per 100,000 population). This is because the population size is small.

It is estimated that around 180 people have progressive, locally advanced or metastatic thyroid cancer that does not respond to radioactive iodine and:

  • they have not had a tyrosine kinase inhibitor before or
  • they have had to stop taking a tyrosine kinase inhibitor within 3 months of starting it because of toxicity (specifically, toxicity that cannot be managed by dose delay or dose modification)

and therefore may be eligible for treatment.

The companies have a commercial arrangement. This makes lenvatinib and sorafenib available to the NHS with a discount. The size of the discount is commercial in confidence. For enquiries about the patient access scheme for lenvatinib contact cyndy_simon@eisai.net, for enquiries about the commercial access agreement for sorafenib contact access.team@bayer.com.

Lenvatanib and sorafenib are commissioned by NHS England. Providers are NHS hospital trusts.


This page was last updated: 08 August 2018